Aluminium clofibrate
| Aluminium clofibrate | |
|---|---|
| Other names | Alfibrate |
| Identifiers | |
| InChI | InChI=1/2C10H11ClO3.Al.H2O/c2* 1-10(2,9(12)13)14-8-5-3-7(11)4 -6-8;;/h2*3-6H,1-2H3,(H,12,13) ;;1H2/q;;+3;/p-3/rC20H21AlCl2O 7/c1-19(2,27-15-9-5-13(22)6-10 -15)17(24)29-21(26)30-18(25)2 0(3,4)28-16-11-7-14(23)8-12-16 /h5-12,26H,1-4H3 |
| InChIKey | USWVMPGQVYZHCA-HIQFMKIUAY |
| Standard InChI | InChI=1S/2C10H11ClO3.Al.H2O/c2* 1-10(2,9(12)13)14-8-5-3-7(11)4 -6-8;;/h2*3-6H,1-2H3,(H,12,13) ;;1H2/q;;+3;/p-3 |
| Standard InChIKey | USWVMPGQVYZHCA-UHFFFAOYSA-K |
| CAS number | [] |
| EC number | |
| ATC code | C10 |
| ChemSpider | |
| Properties | |
| Chemical formula | C20H21AlCl2O7 |
| Molar mass | 471.26 g/mol |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) | |
Aluminium clofibrate or alfibrate is the basic salt of aluminium with clofibric acid. It is one of the fibrate class of lipid modifying agents,[1] that has been used for the treatment of hypercholesterolemia.
Aluminium clofibrate was introduced to counter the mild stomach upsets which are sometimes associated with fibrate treatment. It is hydrolysed in the stomach to aluminium salts (known antacids) and clofibric acid. However, clofibrate treatment for hypercholesterolemia is now regarded as obsolete due to the unacceptable side-effect profile, particularly the incidence of gallstones.[2]
References
- ↑ ATC/DDD Index; WHO Collaborating Centre for Drug Statistics Methodology, <http://www.whocc.no/atcddd/indexdatabase/>. (accessed 5 December 2009).
- ↑ A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br. Heart J. 1978, 40 (10), 1069–1118. DOI: 10.1136/hrt.40.10.1069.
External links
 |
See also the corresponding article on Wikipedia. |
| Error creating thumbnail: Unable to save thumbnail to destination |
This page is currently licensed under the Creative Commons Attribution 3.0 Unported license and any later versions of that license. |
